Antiplatelet therapy contraindicated

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for antiplatelet therapy compared to non-IDD patients (13.1%

Effect: decline; adjusted OR 0.64; CI: 95% CI = 0.56-0.73